NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001<
15 Dec 2021

First Subjects Dosed in First-in-Human Trial for VarmX’s Anticoagulant Reversal Agent, VMX-C001

Major corporate milestone achieved as VarmX transitions into a clinical-stage company
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial<
13 Dec 2021

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients
SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer<
10 Dec 2021

SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer

Raffaella Toso, PhD, joins as VP Corporate Development & Alliance Management and Florence Paliargues appointed as VP Portfolio Project Management.
ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors<
02 Dec 2021

ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors

Seasoned biotech executive with a wealth of experience and a track-record of strategic alliances in the immuno-oncology space.
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders<
01 Dec 2021

Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders

Carmel M. Lynch, PhD, as Chief Development Officer (CDO) and Pernille Høyrup Hemmingsen, PhD, as Chief Technology Officer (CTO). Dennis Benjamin, PhD, will support the Company as Research Fellow & Chairman of the Scientific Advisory Board (SAB).
Dutch med-tech innovator Xeltis lands €15 million European financing from EIB<
22 Nov 2021

Dutch med-tech innovator Xeltis lands €15 million European financing from EIB

Xeltis will use the funding to accelerate the clinical programmes of three restorative devices that can substantially impact cardiovascular
Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology<
22 Nov 2021

Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology

Purchase price includes an upfront payment of EUR 205 million, precommercial milestones for up to EUR 170 million and progressive commercial milestones.
Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases<
17 Nov 2021

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

Today’s acquisition marks a pivotal moment for Kala and a meaningful acceleration toward our goal of strengthening Kala’s pipeline for the treatment of front and back of the eye diseases,
Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting<
16 Nov 2021

Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting

AU-011 may offer patients a safe, effective first-line therapy for early-stage disease that preserves vision.
AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access<
04 Nov 2021

AM-Pharma Appoints Alexander Bastian as Vice President Value & Market Access

His responsibilities include ensuring broad patient access to ilofotase alfa, AM-Pharma’s drug candidate for the treatment of sepsis-associated acute kidney injury, currently in Phase III clinical development.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка